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Background: Recent studies have found that many children with advanced cancer suffer from 
significant symptom burden. Of these symptoms, one of the most troublesome - and most difficult to 
manage - is that of fatigue. 
Psychostimulants like methylphenidate have been shown to subjectively improve symptom scores of 
fatigue in adult patients at end of life. However very little empiric research has been conducted 
amongst an equivalent pediatric population. 
Methods: Mr A is a 12yo boy with relapsed acute myeloid leukaemia. Mr A´s pain has been well 
controlled with pharmacological and non-pharmacological strategies, yet fatigue remains a significant 
burden to Mr A´s quality of life. 
A holistic assessment and approach to addressing Mr A´s fatigue was undertaken, with allied health 
input and maximisation of non-pharmacological therapies. Nevertheless, the impact of fatigue 
remained a significant source of distress for Mr A, impeding his ability to engage in even short activities 
with his school friends, siblings and family as he wished. 
Mr A's case was discussed with extended members of the paediatric palliative care multidisciplinary 
team and a trial of low-dose methylphenidate was proposed. 
Results: Mr A was commenced on methylphenidate 5mg mane. During this period of time, Mr A 
continued on his regular dose of slow and immediate release opioid, and adjuvant medication. Within 
days of commencement, Mr A´s family noted significant improvement in his mood and ability to 
engage in short activities, with reported improvement also seen in Mr A´s physical and cognitive 
function. 
Conclusions: Psychostimulants such as methylphenidate may provide positive symptomatic benefits 
for children with end-stage cancer and burdensome fatigue. Nevertheless, discussion of potential 
negative side effects, further research, and consideration of placebo-controlled trials are warranted, to 
elaborate the potential scope, safety, and role of such medications in a pediatric palliative care setting.  
 
 
  
